An investigation of the cell viability of HCT-116 (TRAIL-sensitive), SW-480 (TRAIL-intermediately resistant), and HT-29 (TRAIL-resistant) after treatments with saline, Apo-2L, iron oxide NPs, and NanoTRAIL resulted in a more modest TRAIL/Apo-2L response in HT29 than with other cell lines; there was a more significant anti-colorectal cancer tumor effect than with TRAIL/Apo-2L treatment alone in HT-29 cells with the upregulation of DR5 expression increased TRAIL/Apo-2L sensitivity and significant apoptosis. This evidence concerns the gene TNFRSF10B and neoplasm.